Antiprocathepsin D autoantibodies correlate with the stage of breast cancer

Abstract

Vaclav Vetvicka, Martin Fusek

Despite recent advances in surgical techniques and therapeutic treatments, survival rates from breast cancer remains disappointing. Current biomarkers are not sufficiently predictive of prognosis or early diagnosis and would benefit from additional support. We have identified the anti-procathepsin D autoantibodies as a potential indicator of breast cancer outcome and have shown that the level of autoantibodies correspond with the progression of the disease. The significant differences in the level of autoantibodies between individual stages demonstrated the significant promise as a new biomarker.